Award

National Cancer Institute 5R01CA272771-04

The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer

Recipient

National Cancer Institute (NCI), part of the NIH

Award Amount

$468,436.00

Ceiling

$468,436.00

Awarded

February 27, 2026

Identifier

5R01CA272771-04

NIH awarded a grant to study the role of USP27X-Cyclin D1 axis in HER2 therapy-resistant breast cancer, aiming to understand CCND1 regulation and explore USP27X as a therapeutic target.

Description

This is a NIH grant project focusing on the role of USP27X in HER2 therapy-resistant breast cancer, with a focus on CCND1 regulation and potential therapeutic targeting of USP27X.

View original record